| Antigen |
Assay |
T cell subset |
Week 10* |
Week 40 |
| All |
ART- |
ART+ |
All |
ART- |
ART+ |
| Vacc-5q |
DTH high |
n.a. |
76 % |
63 % (8)** |
89 % (9) |
84 % |
78 % (9) |
90 % (10) |
| DTH low |
n.a. |
67 % |
63 % (8) |
80 % (10) |
74 % |
67 % (9) |
80 % (10) |
| Proliferation |
CD4 |
59 % |
50 % (8) |
67 % (9) |
58 % |
44 % (9) |
70 % (10) |
| CD8 |
35 % |
25 % (8) |
44 % (9) |
42 % |
22 % (9) |
60 % (10) |
| CD25 |
CD8 |
21 % |
29 % (7) |
14 % (7) |
31 % |
44 % (9) |
20 % (10) |
| IFN-γ+ |
CD4 |
8 % |
0 % (6) |
22 % (9) |
30 % |
29 % (7) |
30 % (10) |
| CD8 |
33 % |
33 % (6) |
33 % (9) |
47 % |
29 % (7) |
60 % (10) |
| Nat-5q*** |
Proliferation |
CD8 |
24 % |
38 % (8) |
11 % (9) |
33 % |
33 % (9) |
33 % (9) |
| CD25 |
CD8 |
38 % |
67 % (6) |
14 % (7) |
33 % |
44 % (9) |
22 % (9) |
| p17 protein |
Proliferation |
CD8 |
19 % |
29 % (7) |
11 % (9) |
24 % |
29 % (7) |
20 % (10) |
| CD25 |
CD8 |
0 % |
0 % (5) |
14 % (7) |
50 % |
56 % (9) |
44 % (9) |
| p24 protein |
Proliferation |
CD8 |
38 % |
57 % (7) |
22 % (9) |
69 % |
71 % (7) |
67 % (9) |
| CD25 |
CD8 |
33 % |
40 % (5) |
29 % (7) |
61 % |
78 % (9) |
44 % (9) |
| Tat protein |
Proliferation |
CD8 |
0 % |
0 % (7) |
0 % (9) |
19 % |
14 % (7) |
22 % (9) |
| CD25 |
CD8 |
18 % |
25 % (4) |
14 % (7) |
34 % |
56 % (9) |
11 % (9) |
*No differences between the ART- and ART+ groups (Fisher exact test)
**Frequency of responses relative to baseline (total n)
***Nat-5q are the native, unmodified peptides corresponding to the vaccine. |
